Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
A study comparing replacement heart valves made by Edwards Lifesciences, St. Jude Medical and Sorin showed that their anti-calcification coatings helped prolong device durability.
The 60-day study compared Sorin’s phospholipid reduction-treated Mitroflow PRT and Crown PRT, St. Jude’s LinxAC-coated Trifecta valve and Edwards’ ThermaFix-coated Perimount Magna valve with standard glutaraldehyde-treated valves, using pericardial tissue from the valves implanted subcutaneously in rats. Read more
Mela Sciences recalled its flagship MelaFind melanoma diagnosis aid because some of its software wasn’t included in its pre-market approval from the FDA.
The federal safety watchdog said the probability and histogram data displayed on the Melafind’s user interface was not included in a PMA supplement. Read more
A trio of medtech companies set terms for their upcoming public offerings today, announcing plans to raise a collective $297 million.
Evolent Health, EndoChoice and Corindus Vascular Robotics all set terms today for a pair of initial public offerings and an uplisting (Corindus is looking to move from the OTC exchange to the New York Stock Exchange). Read more